Superworth

PTC Therapeutics revenue PTCT

Sales by quarter and over the last twelve months, from 2012.

Last 12 months, to Sep 30, 2026
$1.2B
Latest quarter, Q3 FY26
$357.8M
+70% on a year earlier
Fiscal year 2025
$1.7B
+115% on the year before

PTC Therapeutics' revenue was $1.2B over the twelve months to Sep 30, 2026, down 35% on a year earlier.

In its latest quarter, Q3 FY26, it was $357.8M, up 70% on the same quarter a year before.

Over the five fiscal years to FY2025 it grew 35% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$1.7B+115%
FY2024$806.8M−14%
FY2023$937.8M+34%
FY2022$698.8M+30%
FY2021$538.6M+41%
FY2020$380.8M+24%
FY2019$307M+16%
FY2018$264.7M+36%
FY2017$194.4M+135%
FY2016$82.7M+125%
FY2015$36.8M+46%
FY2014$25.2M−27%
FY2013$34.7M+2%
FY2012$33.9Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q3 FY26$357.8M+70%$1.2B
Q2 FY26$360.5M+102%$1B
Q1 FY26$272.6M−77%$827.1M
Q4 FY25$164.7M−23%$1.7B
Q3 FY25$211M+7%$1.8B
Q2 FY25$178.9M−4%$1.8B
Q1 FY25$1.2B+460%$1.8B
Q4 FY24$213.2M−31%$806.8M
Q3 FY24$196.8M+0%$900.7M
Q2 FY24$186.7M−13%$900.5M
Q1 FY24$210.1M−5%$927.6M
Q4 FY23$307.1M+83%$937.8M

Against its peers

Companies in Drug Manufacturers - General nearest PTC Therapeutics' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
PTCTPTC Therapeutics$1.2B−35% a year
INDVIndivior Pharmaceuticals$1.4B+16% a year
LGNDLigand Pharmaceuticals$290.5M+55% a year
AMRXAmneal Pharmaceuticals$3.1B+9% a year
ARQTArcutis Biotherapeutics$464M+76% a year
LQDALiquidia$450.9M
KNSAKiniksa Pharmaceuticals International$840.8M+59% a year
OGNOrganon$6.1B−3% a year
ALKSAlkermes plc.$1.7B+11% a year
CORTCorcept Therapeutics$830.8M+16% a year
PTGXProtagonist Therapeutics$282M+35% a year
Peer median$835.8M

Where PTC Therapeutics ranks

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on PTC Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.